天士力公告，公司董事会于2025年12月9日收到副总经理席凯的辞职报告。席凯因工作调整原因提请辞 去副总经理职务，辞任后将继续担任职工董事、党委副书记。席凯的辞职自报告送达董事会时生效，不 会影响公司正常生产经营。席凯未持有公司股票，不存在未履行的公开承诺。 ...

Core Insights - The company is actively advancing its integration with China Resources Sanjiu, focusing on "value reshaping," "business reshaping," "organizational reshaping," and "spiritual reshaping" to achieve strategic synergy [1] Group 1: Operational Management - The company is implementing China Resources' management philosophy, enhancing the integration of finance, human resources, EHSQ, and supervision systems [1] - A series of organizational optimization activities, such as "new effect rejuvenation," are being conducted to improve operational control and management efficiency [1] - These efforts are laying a solid foundation for future business collaboration and strategic implementation [1] Group 2: Strategic Planning - The company has organized multiple strategic integration discussions between its management and that of China Resources Sanjiu to understand industry trends and develop the "15th Five-Year" strategic plan [1] - This strategic plan aims to guide the company's future development and promote high-quality growth amid innovation and change [1] Group 3: Marketing and Channel Development - During the integration period, the company is collaborating with China Resources Sanjiu to innovate in pharmaceutical retail by integrating online and offline channel resources [1] - The company is enhancing market cooperation for key products like Minophosphonic acid, which is expected to improve market share [1] - A collaborative mechanism for new product development is being established, addressing distribution issues in certain markets and achieving deeper product coverage [1] - The company is also leveraging China Resources Sanjiu's health consumer goods business to strengthen strategic partnerships with leading chain pharmacies [2]

Core Viewpoint - The company, Tasly Pharmaceutical Group Co., Ltd., is set to hold a Q3 2025 earnings presentation on December 4, 2025, to discuss its operational results and financial status with investors [2][3]. Group 1: Meeting Details - The earnings presentation will take place on December 4, 2025, from 15:00 to 16:00 [2][6]. - The location for the meeting is the Shanghai Stock Exchange Roadshow Center, accessible online [2][6]. - The meeting will be conducted in an interactive online format, allowing for real-time engagement with investors [3][5]. Group 2: Investor Participation - Investors can submit questions for the presentation from November 27, 2025, to December 3, 2025, by visiting the Roadshow Center's website or via the company's email [2][7]. - The company will address commonly asked questions during the earnings presentation [3][7]. Group 3: Company Representatives - Key representatives from the company include Mr. Cai Jinyong (General Manager), Mr. Yu Jie (Board Secretary), and Ms. Wei Jie (Chief Financial Officer) [4].

证券代码：600535 证券简称：天士力 编号：临 2025-071 号 天士力医药集团股份有限公司 关于召开 2025 年第三季度业绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 重要内容提示： 会议召开时间：2025 年 12 月 4 日（星期四）15:00-16:00 会议召开地点：上海证券交易所上证路演中心（网址：https://roadshow.ssei nfo.com/） 会议召开方式：上证路演中心网络互动 投资者可于 2025 年 11 月 27 日（星期四）至 2025 年 12 月 3 日（星期三） 16:00 前登录上证路演中心网站首页点击"提问预征集"栏目或通过公司邮箱 stock@tasly.com 进行提问。公司将在说明会上对投资者普遍关注的问题进行回答。 天士力医药集团股份有限公司（以下简称"公司"）已于 2025 年 10 月 25 日发 布公司 2025 年第三季度报告，为便于广大投资者更全面深入地了解公司 2025 年第 三季度经营成果、财务状况，公司计划于 2025 年 ...

Core Insights - The introduction of the innovative biopharmaceutical Puyouke by Tianshili represents a significant breakthrough in thrombolytic therapy for acute ischemic stroke, particularly for elderly patients who face high bleeding risks during treatment [1][2] - Recent studies published in top medical journals indicate that patients treated with Puyouke experience lower rates of hemorrhagic complications compared to control groups, highlighting its unique advantages in stroke treatment [2] - The "Lung·New Life" stroke prevention project, supported by Tianshili, aims to enhance the quality and quantity of ischemic stroke treatments in line with national health strategies, focusing on training healthcare professionals and improving public awareness [3][4] Company Developments - Tianshili's Puyouke is positioned to balance effective thrombolysis with reduced bleeding risks, enhancing its market potential and expanding the company's product line in the neurology sector [2][4] - The company is actively involved in community outreach and education initiatives to improve stroke prevention and treatment awareness, particularly in underserved areas [6][5] - Tianshili's commitment to innovation and social responsibility is evident in its support for the "Lung·New Life" project, which aims to provide comprehensive stroke care and improve healthcare access [5][7] Industry Trends - The evolution of thrombolytic therapies has shifted towards safer and more effective treatments, with Puyouke exemplifying this trend through its unique molecular structure and mechanism of action [4] - The national health strategy emphasizes the need for increased access to intravenous thrombolysis treatments in medical institutions, aligning with Tianshili's initiatives [3] - The dual focus on clinical needs and technological innovation in the pharmaceutical industry is highlighted by Tianshili's approach, which serves as a model for sustainable development in China's healthcare sector [7]

Group 1 - A fruit store in Ningbo was fined 50,000 yuan for issuing 28 false invoices to Tian Shi Li Pharmaceutical Group Co., Ltd. and Tian Shi Li Di Yi Pharmaceutical Co., Ltd. [1][7] - The total amount of the false invoices was 66,800.04 yuan, which included both the price and tax [7]. - The tax authority confiscated illegal income of 6,206 yuan from the fruit store in addition to the fine [7][8]. Group 2 - Tian Shi Li Pharmaceutical Group Co., Ltd. is a publicly listed pharmaceutical company in A-shares, while Tian Shi Li Di Yi Pharmaceutical Co., Ltd. is its wholly-owned subsidiary [7]. - The case raises questions about the authenticity of transactions between the fruit store and the pharmaceutical companies, as the nature of their business dealings remains unclear [7].

Core Insights - Shenzhen has emerged as a key engine city in the Guangdong-Hong Kong-Macao Greater Bay Area, showcasing significant achievements in capital market development during the 14th Five-Year Plan period, with over 400 billion yuan in equity financing and a leading proportion of technology companies listed [1][2] Group 1: Capital Market Development - During the 14th Five-Year Plan, Shenzhen's capital market facilitated over 400 billion yuan in equity financing, supporting advanced manufacturing projects [2] - The proportion of companies listed on the Growth Enterprise Market and the Sci-Tech Innovation Board reached 50.24%, the highest among major cities in China [2] - Shenzhen's overall R&D investment intensity reached a global leading level, with listed companies' R&D expenditure totaling 210.33 billion yuan in 2024, a 91.35% increase from 2020 [2] Group 2: Market Performance - In the first three quarters of 2025, Shenzhen's listed companies achieved a total revenue of 5.2 trillion yuan and a net profit of 457.797 billion yuan, reflecting year-on-year growth of 7.36% and 3.98%, respectively [3] - Shenzhen's securities firms ranked first nationally in performance, with public and private fund management scales among the top three [3] Group 3: Investor Engagement and Protection - During the 14th Five-Year Plan, 1,486 listed companies in Shenzhen implemented cash dividends totaling nearly 990 billion yuan, significantly exceeding the equity financing amount [4] - The regulatory authorities maintained a "zero tolerance" approach to violations, enhancing investor confidence and market integrity [4][6] Group 4: Future Directions - The Shenzhen government aims to establish a globally influential industrial financial center, focusing on high-quality development in banking, securities, insurance, venture capital, and mergers and acquisitions [7][8] - The capital market will emphasize the development of new productive forces, guiding funds towards high-tech and high-quality sectors to support industrial transformation and innovation [8]

Core Viewpoint - Tianjin Tasly Pharmaceutical Group Co., Ltd. has received approval from the National Medical Products Administration for its innovative biological drug "Recombinant Human Urokinase (Puyouke)" for the treatment of acute ischemic stroke (AIS), addressing the specificity issues of traditional thrombolytic drugs in the stroke field [4][9]. Group 1: Product Approval and Market Impact - The new indication approval for Puyouke follows its previous approval for treating acute ST-segment elevation myocardial infarction, enhancing its role in stroke treatment [4]. - Puyouke targets occlusive thrombus specifically, activating plasminogen at the site of occlusion, which reduces systemic activation of the fibrinolytic system, thus lowering the risk of bleeding and improving patient outcomes [7][9]. Group 2: Challenges in Stroke Treatment - China faces significant challenges in the prevention and treatment of acute ischemic stroke, with approximately 3.3 million new cases annually, making it the leading cause of death and disability among adults [6]. - Public awareness of stroke symptoms and emergency response is low, with 67%-75% of patients missing the thrombolysis window due to delayed treatment [6]. - The rate of intravenous thrombolysis is only about 10%, and endovascular treatment is less than 1%, indicating a substantial gap compared to developed countries [6]. Group 3: Innovation and Production Challenges - The development of Puyouke required overcoming multiple technical barriers, including the stability and yield of the active ingredient, recombinant human urokinase [8]. - Tasly has established a comprehensive quality control system and stable production capacity, addressing the high barriers to commercial production of unstable enzyme products [8]. Group 4: Public Health Initiatives - The "Stroke Prevention and Treatment Capacity Enhancement and Health Promotion" project, initiated by the Chinese Stroke Association and supported by Tasly, aims to improve public awareness and enhance grassroots medical capabilities in stroke prevention and treatment [10][11]. - The project focuses on educating the public about stroke prevention and early treatment, as well as improving the diagnostic and treatment skills of primary care physicians [11].

Core Viewpoint - The Medical Health Index (980016) closed at 6572.66 points, down 0.65%, with a trading volume of 23.397 billion yuan and a turnover rate of 0.87% on November 14 [1] Group 1: Index Performance - Among the index constituents, 16 stocks rose while 33 stocks fell, with Ganli Pharmaceutical leading the gainers at a 2.0% increase and Yirui Technology leading the decliners at a 3.74% decrease [1] - The top ten constituents of the Medical Health Index include major companies such as WuXi AppTec, Hengrui Medicine, and Mindray Medical, with respective weights of 13.66%, 11.00%, and 7.57% [1] Group 2: Market Capitalization and Stock Prices - The total market capitalization of the top ten constituents ranges from 553.09 billion yuan for Kelun Pharmaceutical to 4603.55 billion yuan for Rihai Shenzhou, with stock prices varying from 12.25 yuan to 298.80 yuan [1] - The performance of the top ten stocks shows a mix of slight declines, with WuXi AppTec down 1.49% and Hengrui Medicine down 1.04% [1] Group 3: Capital Flow - The Medical Health Index constituents experienced a net outflow of 472 million yuan from major funds, while retail investors saw a net inflow of 388 million yuan [1] - Detailed capital flow data indicates that Ganli Pharmaceutical had a net inflow of 62.98 million yuan from major funds, despite a net outflow from retail investors [2]

Core Viewpoint - Tianjin Tasly Pharmaceutical Group Co., Ltd. has shown a mixed performance in stock price and financial metrics, with a notable increase in net profit despite a slight decline in revenue [1][2]. Financial Performance - As of September 30, 2025, the company reported a revenue of 6.311 billion yuan, a year-on-year decrease of 2.35% [2]. - The net profit attributable to shareholders was 984 million yuan, reflecting a year-on-year increase of 16.88% [2]. - The company has distributed a total of 8.053 billion yuan in dividends since its A-share listing, with 2.092 billion yuan distributed over the past three years [3]. Stock Market Activity - On November 14, the stock price increased by 2.06%, reaching 15.86 yuan per share, with a trading volume of 232 million yuan and a turnover rate of 0.99% [1]. - The stock has seen a year-to-date increase of 12.88%, a 5-day increase of 3.12%, a 20-day decrease of 0.25%, and a 60-day decrease of 0.81% [1]. - The net inflow of main funds was 7.192 million yuan, with significant buying and selling activity from large orders [1]. Shareholder Structure - The number of shareholders increased to 81,300, a rise of 34.45% compared to the previous period [2]. - The average number of circulating shares per shareholder decreased by 25.62% to 18,383 shares [2]. - Notable institutional holdings include Hong Kong Central Clearing Limited as the fourth-largest shareholder, increasing its stake by 11.93 million shares [3].